Last reviewed · How we verify
LBR-101 IV — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
LBR-101 IV (LBR-101 IV) — Teva Branded Pharmaceutical Products R&D, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LBR-101 IV TARGET | LBR-101 IV | Teva Branded Pharmaceutical Products R&D, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LBR-101 IV CI watch — RSS
- LBR-101 IV CI watch — Atom
- LBR-101 IV CI watch — JSON
- LBR-101 IV alone — RSS
Cite this brief
Drug Landscape (2026). LBR-101 IV — Competitive Intelligence Brief. https://druglandscape.com/ci/lbr-101-iv. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab